Background: Data are limited regarding bone metastases from colorectal cancer (CRC). The objective of this studywas to survey the natural history of bone metastasis in CRC.Patients and methods: This retrospective, multicenter, observational study of 264 patients with CRC involving boneexamined cancer treatments, bone metastases characteristics, skeletal-related event (SRE) type and frequency,zoledronic acid therapy, and disease outcomes.Results: Most patients with bone metastases had pathologic T3/4 disease at CRC diagnosis. The spine was the mostcommon site involved (65%), followed by hip/pelvis (34%), long bones (26%), and other sites (17%). Median time fromCRC diagnosis to bone metastases was 11.00 months; median time to first SRE thereafter was 2.00 months. Radiationand pathologic fractures affected 45% and 10% of patients, respectively; 32% of patients had no reported SREs.Patients survived for a median of 7.00 months after bone metastases diagnosis; SREs did not significantly affect survival.Subgroup analyses revealed that zoledronic acid significantly prolonged median time to first SRE (2.00 months versus1.00 month, respectively, P = 0.009) and produced a trend toward improved overall survival versus no zoledronic acid.Conclusion: This study illustrates the burden of bone metastases from CRC and supports the use of zoledronic acid inthis setting.
|Numero di pagine||6|
|Rivista||Annals of Oncology|
|Stato di pubblicazione||Published - 2012|